The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)
Open accessAbstract
UNLABELLED: An (18)F-labeled PET amyloid-beta (Abeta) imaging agent could facilitate the clinical evaluation of late-life cognitive impairment by providing an objective measure for Alzheimer disease (AD) pathology. Here we present the results of a clinical trial with (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ((18)F-AV-45 or florbetapir [corrected] F 18). METHODS: An open-label, multicenter brain imaging, metabolism, and safety study of (18)F-AV-45 was performed on 16 patients with AD (Mini-Mental State Examination score, 19.3 +/- 3.1; mean age +/- SD, 75.8 +/- 9.2 y) and 16 cognitively healthy controls (HCs) (Mini-Mental State Examination score, 29.8 +/- 0.45; mean age +/- SD, 72.5 +/- 11.6 y). Dynamic PET was performed over a period of approximately 90 min after injection of the tracer (370 MBq [10 mCi]). Standardized uptake values and cortical-to-cerebellum standardized uptake value ratios (SUVRs) were calculated. A simplified reference tissue method was used to generate distribution volume ratio (DVR) parametric maps for a subset of subjects. RESULTS: Valid PET data were available for 11 AD patients and 15 HCs. (18)F-AV-45 accumulated in cortical regions expected to be high in Abeta deposition (e.g., precuneus and frontal and temporal cortices) in AD patients; minimal accumulation of the tracer was seen in cortical regions of HCs. The cortical-to-cerebellar SUVRs in AD patients showed continual substantial increases through 30 min after administration, reaching a plateau within 50 min. The 10-min period from 50 to 60 min after administration was taken as a representative sample for further analysis. The cortical average SUVR for this period was 1.67 +/- 0.175 for patients with AD versus 1.25 +/- 0.177 for HCs. Spatially normalized DVRs generated from PET dynamic scans were highly correlated with SUVR (r = 0.58-0.88, P < 0.005) and were significantly greater for AD patients than for HCs in cortical regions but not in subcortical white matter or cerebellar regions. No clinically significant changes in vital signs, electrocardiogram, or laboratory values were observed. CONCLUSION: (18)F-AV-45 was well tolerated, and PET showed significant discrimination between AD patients and HCs, using either a parametric reference region method (DVR) or a simplified SUVR calculated from 10 min of scanning 50-60 min after (18)F-AV-45 administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Positron emission tomography (PET) ligands have been shown to provide a minimally invasive estimate of the neuropathological features of AD, such as Aβ neuritic plaque deposition.15,16,17,18”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [15]
In the citing paper
“Amyloid imaging biomarkers, obtained via positron emission tomography imaging with Pittsburgh compound B (11C-PiB)24 or Florbetapir F 18 (18F-AV-45)25 were available for 54 individuals, and all were positive.”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Patients with AD had to be older than 50 y and have a probable diagnosis of AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association, with a Mini-Mental State Examination (MMSE) score of between 10 and 24, inclusively (1…”
MethodThe precuneus: a review of its functional anatomy and behavioural correlates
Cavanna, A. E., & Trimble, M. R. (2006) · Brain · doi:10.1093/brain/awl004 · Cited by 5,128 · cited 1×
“This finding is consistent with the known localization of Ab in these areas in postmortem tissue (23), with recent literature suggesting the precuneus is involved in integrative functions including visual spatial coordination and working memory retrieval (24)—and with results from other Ab radiotracers (9,25).”
ResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 3×
“This pattern is similar to that previously reported for 11CPIB (21,22) and 18F-BAY94-9172 (9).”
BackgroundResultFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Although cerebrospinal fluid Ab levels are reliably decreased in AD (6), cerebrospinal fluid studies are inevitably indirect markers.”
BackgroundPike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786
Research works printed but not linked: 4
- 2005, J Nucl Med., 46, 1023
- 2005, J Nucl Med., 46, 1959
- 1997, Int Psychogeriatr., 9, 257
- 2008, J Nucl Med., 49, 283P
Cited by
Sorted by citations
Items 601–697 of 697
Recognizing common PET patterns in neurodegenerative dementia
Chen, Y. J., Dubroff, J. G., & Nasrallah, I. M. (2017) · Applied Radiology · doi:10.37549/ar2385 · Cited by 1
Molecular Imaging: Positron Emission Tomography
Fowler, J. S., & Volkow, N. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-88832-9_149 · Cited by 1
Démonet, J., & Celsis, P. (2012) · Wiley eBooks · doi:10.1002/9781119952930.ch5 · Cited by 1
Sialic Acid‐Modified Nanoparticles for β‐Amyloid Studies
Kouyoumdjian, H., & Huang, X. (2015) · Wiley eBooks · doi:10.1002/9781118860212.ch12 · Cited by 1
Amyloid imaging of dementia using the radioligand 18F-AV-45 (Florbetapir F 18)
Shibata, T., Yonezawa, H., Takahashi, J., Kudo, M., Obara, S., Suzuki, M., Ishizuka, N., Fujisawa, Y., Sasaki, T., Terasaki, K., et al. (2015) · Cerebral Blood Flow and Metabolism (Japanese journal of cerebral blood flow and metabolism) · doi:10.16977/cbfm.26.2_11
Proximity Ligation and Barcoding Assays : Tools for analysis of proteins and protein complexes
Wu, D. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Developing Targeted PET Tracers in the Era of Personalized Medicine
Bohorquez, S. M. S., van Bruggen, N., & Mařı́k, J. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch12
Identification of Novel Fluid Biomarkers for Alzheimer's Disease
Craig‐Schapiro, R. (2012) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7pr7t12
PL‐05‐03: Metabolic and molecular imaging markers throughout the course of Alzheimer's disease
Herholz, K. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.515
Diagnosticare la malattia di Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67223-8
Michaud, L., Venel, Y., Borgne, A. L., Ribeiro, M.-J., Guilloteau, D., Tauber, C., & Baulieu, J. (2013) · Médecine Nucléaire · doi:10.1016/j.mednuc.2013.10.003
What is the role of neuroimaging in dementia? A review
Narayanan, L., & Murray, A. D. (2014) · Imaging · doi:10.1259/img.20120015
Evaluation of cognitive performance within the disease course of Alzheimers
Neuropsychology, M. T. (2013)
Trembath, L., & Newell, M. (2015)
Imagerie de l’Alzheimer : quoi de neuf ?
Payoux, P. (2013) · Médecine Nucléaire · doi:10.1016/j.mednuc.2013.03.043
5-[18F]Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine
Chopra, A. (2012) · Europe PMC (PubMed Central)
Molecular Imaging in Alzheimer Clinical Trials
Schmidt, M. E., Matthews, D. C., & Staelens, S. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00020-4
Fowler, J. S., & Volkow, N. D. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6434-1_149-1
Neurologische und dementielle Erkrankungen
Heiss, W., & Kracht, L. (2016) · Springer eBooks · doi:10.1007/978-3-662-48842-3_24
Imaging Approaches to Cerebral Cortex Pathology
Bartha, R., & Lee, T.-Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00003-3
Diagnostiquer la maladie d'Alzheimer
Sarazin, M., Hamelin, L., Lamari, F., & Bottlaender, M. (2013)
Technical Considerations on Scanning and Image Analysis for Amyloid PET in Dementia
Akamatsu, G., Ohnishi, A., Aita, K., Ikari, Y., Yamamoto, Y., & Senda, M. (2017) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2017_jsrt_73.4.298
Amyloidassoziierte Krankheiten des Zentralnervensystems: multimodale Befundung
Miller‐Thomas, M. M., Sipe, A. L., Benzinger, T. L. S., McConathy, J., Connolly, S., & Schwetye, K. E. (2017) · Neuroradiologie Scan · doi:10.1055/s-0043-118838
Weiner, M. W., Veitch, D. P., Hayes, J., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., et al. (2014)
Surgery, Anesthesia, and Risk for the Development of Dementia
Velkers, C. (2018) · QSpace (Queen's University Library)
Top ten discoveries of the year: Neurotrauma
Perl, D. P. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2662
Translational Biomarker Imaging
McConville, P., & Lister, D. R. (2020) · Wiley eBooks · doi:10.1002/9781119187547.ch29
Delacruz, R., Weatherman, K. D., & Kowalsky, R. J. (2020) · doi:10.21019/9781582122830.ch24
Revisiting Alzheimer’s Disease
Salwa, & Kumar, L. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_7
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6
Revista Brasileira de Psiquiatria
Benadiba, M., Luurtsema, G., Wichert‐Ana, L., Buchpiguel, C. A., & Busatto, G. F. (2012)
Clinical Validation of Neuronal Pentraxin Receptor as a Candidate Biomarker for Alzheimer’s Disease
Lim, B. (2020) · TSpace (University of Toronto)
PET Neuroimaging of Neurologic Disease: Methods, Clinical and Research ApplicationsPreprint
Walker, K. A., & Bilgel, M. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/u72e8
PET Chemistry: Radiopharmaceuticals
Roß, T. L., & Ametamey, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-65245-6_8
Amyloid imaging in alzheimer’s disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0485-5
Psychiatric Disorders in Dementia
Vermeiren, Y., Dam, D. V., de Vries, M., & Deyn, P. P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_9
Evaluation of MR-less in brain amyloid-β PET Centiloid quantification
de Souza, G. S., Pinto, S., & da Silva, A. M. M. (2022) · SPIE Medical Imaging: Biomedical Applications in Molecular, Structural, and Functional Imaging · doi:10.1117/12.2611904
“There has been extensive work on quantifying (18)F- FDG and (11)C-PiB PET images without MR [4-6].”
BackgroundSaint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Stoessl, A. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00038-4
Nordberg, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00071-3
Misquitta, K., Rosen, H. J., & Tartaglia, M. C. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.004
Scintigraphy of Human CSF Flow in Patients with Leptomeningeal Metastasis
Wong, F. C., & McCutcheon, I. E. (2022) · Springer eBooks · doi:10.1007/978-3-031-14291-8_4
Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand
Siriprapa, T., Thientunyakit, T., & Gelovani, J. G. (2023) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v75i9.263161
Fluorescent Organic Molecules as Diagnostic and Theranostic Tools for Alzheimer’s Disease
Imran, K., Dhamapurkar, Y. A., & Sharma, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_5
Ouyang, Z., Wang, L., & Initiative, A. D. N. (2024) · Mathematics · doi:10.3390/math12070951
“Two distinct normalization methods of summary measures for the standardized uptake value ratio (SUVR) of the florbetapir tracer, in the composite reference region and the whole cerebellum reference region, may potentially serving as AD biomarkers [37].”
MethodPET-CT: A Tool for Etiological Diagnosis
Genovesi, D., & Giorgetti, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-51757-0_14
Elgazzar, A. H., & Sarikaya, İ. (2024) · Springer eBooks · doi:10.1007/978-3-031-68074-8_8
18F-FDG PET for Neurodegenerative Diseases: Principles and Progress
Thientunyakit, T., Wannasoupol, N., Sethanandha, C., Piyapittayanan, S., Siriprapa, T., Thongpraparn, T., Muangpaisan, W., & Gelovani, J. G. (2025) · Neuromethods · doi:10.1007/978-1-0716-4494-2_6
Amyloid PET Imaging and Quantification of Amyloid Deposition
Matsuda, H., & Yamao, T. (2025) · Neuromethods · doi:10.1007/978-1-0716-4494-2_5
Fluid and Imaging Markers of Amyloid Pathology
West, T., Meyer, M. R., Kirmess, K. M., Yarasheski, K. E., Braunstein, J. B., & Verghese, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_1
Weng, M.-C., Chen, J.-T., Lin, W., Tu, Y.-H., Farn, S., Hsia, C.-C., & Chang, K. (2025) · Research Square · doi:10.21203/rs.3.rs-7360002/v1
Accounting for white matter uptake improves between tracer agreement in amyloid PET
Chen, Y., Protas, H. D., Luo, J., Li, S., Sohankar, J., Pan, C., Ghisays, V., Lee, W., Wu, T., Chen, D., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70165
Brašić, J. R., & Civelek, A. C. (2025) · iRadiology · doi:10.1002/ird3.70038
Self-citationEstimating preclinical amyloid positivity: A case study transporting ADNI to ARIC
Stapp, E. K., Mayeda, E. R., Stuart, E. A., Gottesman, R. F., Zimmerman, S. C., Wong, D. F., Mosley, T. H., Griswold, M. E., Glymour, M. M., Power, M. C., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70158
Self-citation赤松, 剛. (2015) · Institutional Repositories DataBase (IRDB) · doi:10.15017/1654738
Cousins, O., Schubert, J. J., Chandra, A., Veronese, M., Valkimadi, P., Creese, B., Khan, Z., Arathimos, R., Hampshire, A., Rosenzweig, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24603603
Myoraku, A., Klein, G., Landau, S., & Tosun, D. (2022) · Figshare · doi:10.6084/m9.figshare.18585697
Jiang, F., Yi, Y., Zhang, J., Tan, A., Qin, X., Zhong, X., Wang, P., Xiao, J., Zhou, B., & Li, J. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121067
Matsuda, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_3
Chang, C., Lee, S. J., Na, D. L., & Yoon, J. H. (2026) · International Journal of Language & Communication Disorders · doi:10.1111/1460-6984.70196
Matsusaka, Y., Suzuki, K., Seto, A., Kato, Y., & Kuji, I. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006273
Registration accuracy of amyloid/tau-PET to brain MRI using modified SPM method
Iwao, Y., Akamatsu, G., Sakata, M., Wagatsuma, K., Ishii, K., Yamaya, T., & Takahashi, M. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02159-3
Zhang, T., Nie, B., Liu, H., Mao, G., OuYang, C., Jiang, X., & Shan, B. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07797-3 · Cited by 1
Mapping individual molecular connectomes in Alzheimer's disease
Xu, Z., Mijalkov, M., Sun, J., Chang, Y., Sala, A., Volpe, G., Severino, M., Veronese, M., Ptacek, S. G., Pereira, J. B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71310
Complexes métalliques pour utilisation en imagerie médicale : application à la maladie d’Alzheimer
Porqueras, D. S. D. (2016) · theses.fr (ABES) · doi:10.70675/b908263ez07c9z441ez94d8zc53fbd818c56
Hanbouch, L. (2017) · theses.fr (ABES) · doi:10.70675/c4d2c894zf69dz4ae4z9ab1zf4135d0efa12
Effects of zinc and copper ions in the amyloid cascade linked to Alzheimer's disease
Borghesani, V. (2018) · theses.fr (ABES) · doi:10.70675/d82c3f9az0deaz45e9z9097zeb1f4fd0a45b
Abdelouahab, O. B. (2021) · theses.fr (ABES) · doi:10.70675/97f4885fz3f5cz4234zb8e2ze3fa7c4e3d41
La place des biomarqueurs dans les essais de prévention de la maladie d'Alzheimer
Delrieu, J. (2021) · theses.fr (ABES) · doi:10.70675/2b5f4719z01f9z4376z9dabzd5a185dc4d79
Imaging Strategies for Acupuncture Intervention in Alzheimer's Disease Model Mice
Runquan, S., Wang, J., Liu, S., Tian, H., Wang, X. E., & Zhang, Y. (2026) · Journal of Visualized Experiments · doi:10.3791/70998
Zafari, R., Kamroo, A., Taherkhani, T., Heidari‐Foroozan, M., Nabizdeh, F., & Aarabi, M. H. (2026) · Research Square · doi:10.21203/rs.3.rs-9382890/v1
Bailey-Taylor, M. J., Morrow, P., Hendrix, J., Galluzzi, K. E., & Sharafsaleh, G. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s585263
Akasaka, T., Watanabe, H., & Ono, M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00047
Automated PET tracer classification in multi-site, multi-cohort studies using deep learning
Gebre, R. K., Reid, R. I., Senjem, M. L., Gunter, J. L., Lowe, V. J., Kantarci, K., Petersen, R. C., Graff‐Radford, J., Jack, C. R., Vemuri, P., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01486-w
Chemical probes for Alzheimer’s disease targets
Aiken, S., Zarganes‐Tzitzikas, T., & Brennan, P. E. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260014
Nakayama, K., Nemoto, K., Endo, H., Tagai, K., Oyama, A., Nemoto, M., Tamura, M., Ota, M., Tokuda, T., Higuchi, M., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02775-5
Josephs, K. A., Weigand, S. D., Satoh, R., Lavrova, A., Tapia, A. L., Graff‐Radford, J., Machulda, M. M., Kantarci, K., Boeve, B. F., Petersen, R. C., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117530
BindingDB Entry 50046766: Applications of Fluorine in Medicinal Chemistry.
BindingDB (2016) · UC San Diego · doi:10.7270/q22j6dpz
Metadata
- Authors
- Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., Hilton, J., Lyketsos, C., Kung, H. F., Joshi, A. D., Skovronsky, D. M., & Pontecorvo, M. J.
- Affiliations
- Johns Hopkins University (US)
- University of Pennsylvania (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-05-25
- Volume
- 51
- Issue
- 6
- Pages
- 913-920
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC3101877
- OpenAlex
- W2040174321
- Cited by
- 684
- References
- 35
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 17 · 2023: 25 · 2022: 32 · 2021: 42 · 2020: 43 · 2019: 31 · 2018: 46 · 2017: 54 · 2016: 56 · 2015: 50 · 2014: 60 · 2013: 64 · 2012: 57
- FWCI
- 40.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Vanderbilt University
- National Institutes of Health
- Avid Radiopharmaceuticals
- National Institute on Alcohol Abuse and Alcoholism (R01AA012839, AA012839)
- National Institute on Aging (K08AG029157, P50AG005146)
- National Institute of Mental Health (R01MH078175, MH 078175)
- National Institute on Drug Abuse (K24DA000412)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid-beta deposition, 18F-florbetapir, positron emission tomography, radioligands, amyloid imaging, distribution volume ratio, standardized uptake value ratio, dynamic PET, tracer metabolism, brain amyloid imaging, late-life cognitive impairment, cerebellum
- MeSH terms
- Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Ethylene Glycols, Female, Fluorine Radioisotopes, Humans, Male, Radiometry, Whole-Body Irradiation, Case-Control Studies, Positron-Emission Tomography, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
